Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Exclusion Criteria10

• Patients with the diagnosis of neuromyelitis optica.
• Patients who are being treated with any investigational drug at the time of study entry.
• In the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization or Class III/IV heart failure
• A history or presence of Mobitz Type II second-degree or third-degree atrioventricular block or sick sinus syndrome, unless patient has a functioning pacemaker
• A baseline QTc interval ≥ 500 msec
• Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs
• Patient with known immune deficiency, increased risk of opportunistic infection, severe active infection or chronic active infection.
• Patients with severe active malignancies, except for basal cell epithelioma
• Patients with severe hepatic insufficiency
• Pregnant or nursing (lactating) women or women of childbearing potential unless on contraception